18 citations,
July 2015 in “Drug Healthcare and Patient Safety” Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.
18 citations,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
16 citations,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
[object Object] 16 citations,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
July 2008 in “Biomedical Imaging and Intervention Journal” New cancer treatments are more precise and less toxic, improving survival rates, but Asia faces challenges in adopting these advancements.
January 1989 in “Side effects of drugs annual” Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.
218 citations,
September 2012 in “Gastroenterology” Colorectal cancer development involves both genetic changes and epigenetic alterations like DNA methylation and microRNA changes.
192 citations,
January 2015 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause serious skin problems that need careful management.
50 citations,
February 2018 in “Biomedicine & pharmacotherapy” Ginseng may help treat cancer and reduce treatment side effects, but more research is needed.
44 citations,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
42 citations,
April 2012 in “Seminars in Oncology” Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
32 citations,
September 2013 in “Breast cancer research” A specific gene variant is linked to a higher risk of hair loss from chemotherapy in breast cancer patients.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
29 citations,
March 2010 in “Cancer epidemiology” Men who start losing hair at age 30 may have a lower risk of prostate cancer.
20 citations,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
16 citations,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
15 citations,
February 2017 in “Nursing Clinics of North America” Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
15 citations,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
14 citations,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
9 citations,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
7 citations,
August 2020 in “Current topics in medicinal chemistry” New cancer treatments aim to reduce side effects and improve effectiveness.
7 citations,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
2 citations,
September 2010 in “Journal of the Dermatology Nurses’ Association” Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.
1 citations,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
1 citations,
June 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.
March 2024 in “BMC cancer” High levels of ST14 and TMEFF1 proteins in ovarian cancer are linked to worse patient outcomes and may be a new treatment target.
[object Object] December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.
January 2022 in “International Journal of Medical Sciences” Cedrol may be an effective treatment for colorectal cancer.